In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.
about
Eugenia uniflora L. Essential Oil as a Potential Anti-Leishmania Agent: Effects on Leishmania amazonensis and Possible Mechanisms of ActionAn image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophagesMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisIncreasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncomplianceAntileishmanial high-throughput drug screening reveals drug candidates with new scaffoldsA screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hitExperimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocolLeishmania donovani develops resistance to drug combinationsHigh content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discoveryMiltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in ColombiaAntileishmanial activity of semisynthetic lupane triterpenoids betulin and betulinic acid derivatives: synergistic effects with miltefosineDevelopment and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity.In vitro anti-Leishmania activity of tetracyclic iridoids from Morinda lucida, benthAntileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major AmastigotesInhibitors of Leishmania GDP-mannose pyrophosphorylase identified by high-throughput screening of small-molecule chemical libraryAlkyl galactofuranosides strongly interact with Leishmania donovani membrane and provide antileishmanial activityCombined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.A novel Leishmania major amastigote assay in 96-well format for rapid drug screening and its use for discovery and evaluation of a new class of leishmanicidal quinolinium salts.Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquineIn vitro sensitivity of paired Leishmania (Viannia) braziliensis samples isolated before meglumine antimoniate treatment and after treatment failure or reactivation of cutaneous leishmaniasisIdentification of metal dithiocarbamates as a novel class of antileishmanial agentsHigh-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.Antimony resistance in leishmania, focusing on experimental research.The efficacy of 2-nitrovinylfuran derivatives against Leishmania in vitro and in vivoIn Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania sppImaging flow cytometry analysis of intracellular pathogens.Increase of leishmanicidal and tubercular activities using steroids linked to aminoquinoline.Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species.In vitro synergistic effect of amphotericin B and allicin on Leishmania donovani and L. infantum.Carboxylate derivatives of tributyltin (IV) complexes as anticancer and antileishmanial agents.Leishmania antimony resistance: what we know what we can learn from the field.Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?1,3-Bis(aryloxy)propan-2-ols as potential antileishmanial agents.Comparison of gene expression patterns among Leishmania braziliensis clinical isolates showing a different in vitro susceptibility to pentavalent antimony.Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.Evaluating drug resistance in visceral leishmaniasis: the challenges.Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
P2860
Q21285094-FAF18457-BF17-4FF9-A24F-01A68E556E0DQ27305418-31864FFF-3A5E-4608-9CC6-FC03A966A5DDQ28271849-F4991E78-191B-4639-9D02-59B157FE30C1Q28285948-0B6E2B5B-7AF2-49F4-93C0-EEC980036C34Q28473835-512F2ED1-C936-43FE-8352-6F48006025B3Q28479211-B4D6407A-AD08-4CBB-B16D-966CFFE12DF9Q28483977-7FB2B9BF-CC2B-4C32-B0C5-38994D348BDEQ28484463-1E53D684-A4A3-4F38-8C06-A8A1B0A4E2AFQ28485997-3103911C-5B97-4AC7-AB79-B02DE73276E9Q28539068-B760878C-04DA-477A-AC2B-DC8D2BA3F18EQ28541041-8A602172-3E03-4411-9CAF-109D0BE57C90Q28548536-E31945CD-A247-4C6C-86ED-134D633E5EE2Q28831274-D549E5CE-0370-4673-8501-792806FDAEA4Q30488470-C8D6AAA4-DAB0-49D2-B43F-4ECBC9FB5454Q33531622-BC79C1E4-A8FF-4BAE-BE15-2F777A602004Q33622864-B37831AF-B86B-40C8-A565-22D7487E1DCFQ33728704-DF44F3D7-9647-4171-8D41-77E6C3459143Q34669706-CF7EBE78-189D-473B-AB80-38F08A1D7EA8Q35005213-E76663B5-4470-4B57-B858-F4FA8516232EQ35087276-DC062C53-886D-48D7-94B2-BA4DD7F484B5Q35168873-1054CB71-7C5D-43D3-B3DA-84FD496B67F0Q35353325-273AF80F-7A1A-4403-936D-EAF991B55722Q35607561-CFB39551-4A08-4085-BF2F-316873227741Q35810652-7A350D84-5CF0-4EBA-812B-D274C579293AQ35859984-6803647B-E3FB-4FE9-8EB0-080625694914Q36001763-B34D98D7-6D68-4B89-B331-074A3F334394Q36118602-8FBBF0A1-F874-452E-A617-DBB7E585A96DQ36136833-67A3BAC3-2D76-42BC-9EAB-FBA5DAD6055BQ36594384-587735F1-A8BF-463F-A2DD-67C067FB62C5Q37544280-136C0BD5-6807-4D4B-89D0-3054E3E27AB0Q37643719-10EA3045-C058-4897-9837-8807CE3A4181Q37737964-8B409B33-311E-4DB8-84B7-B454BCA48F17Q37907925-D9B18093-8500-444F-B411-8506A2BF988DQ38188571-F9D51D71-E3EA-43FF-B13C-E1FD451F29E1Q38209866-0ACFB900-6194-41B2-A34F-CFA59D4D6B88Q38673741-7B17F8BD-1992-40AC-8BDC-9585E424943FQ38859925-C281FAC3-C0FE-4884-BC0B-700D26F2B109Q38966911-DA517E94-B3B0-4A3B-A473-2531A1911E42Q39014583-39A87F9D-63AE-4114-9751-756911EE7A9EQ39063747-1A4D3E3E-5D0C-4127-99A6-4FA914FB2C06
P2860
In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
In vitro susceptibilities of L ...... of stage-specific differences.
@en
type
label
In vitro susceptibilities of L ...... of stage-specific differences.
@en
prefLabel
In vitro susceptibilities of L ...... of stage-specific differences.
@en
P2093
P2860
P356
P1476
In vitro susceptibilities of L ...... of stage-specific differences.
@en
P2093
Louis Maes
Marieke Vermeersch
P2860
P304
P356
10.1128/AAC.00548-09
P407
P577
2009-06-22T00:00:00Z